Re: Farmas USA
Synergy Pharmaceuticals' Cash Flow And Prescription Trends
Q1 2018 Prescription Trends
Through February 23, TRULANCE prescriptions were about 18,500. Granted a higher percentage were probably 90 day prescriptions versus 30 day prescriptions, but we don't know the breakdown yet. Extrapolating, Q1 prescriptions be in the low 30K's, versus high 30K's for Q4.
Cash Flow Looking Forward
On the conference call, CFO Gemignani indicated operating expenses for 2018 of between $175 -$185 million. Using the midpoint of $180 indicates a quarterly average of $45 million per quarter, slightly higher than Q4. With revenue of $7.5 million, and a contribution margin of $4.5 million, the indicated cash burn rate is $40.5 million per quarte
https://seekingalpha.com/article/4154485-synergy-pharmaceuticals-cash-flow-prescription-trends
Re: Farmas USA
Re: Farmas USA
Re: Farmas USA
Re: Farmas USA
Re: Farmas USA
in RDUS 32,75
Re: Farmas USA
Nasdaq 100 tiene pinta de cerrar en rojo. 🤔🤔🤔🤔